ライフサイエンスコーパス: antidepressant therapy

1 h MDD and an inadequate response to standard antidepressant therapy.

2 (1A) autoreceptor desensitization under SSRI antidepressant therapy.

3 his single cell type plays a pivotal role in antidepressant therapy.

4 epression and identified regions affected by antidepressant therapy.

5 epressant medication change or were starting antidepressant therapy.

6 thors also examined naturalistically applied antidepressant therapy.

7 erent medication intake that often occurs in antidepressant therapy.

8 t an approach to the development of improved antidepressant therapies.

9 nobutyric acid (GABA) that are normalized by antidepressant therapies.

10 cological target for developing rapid-acting antidepressant therapies.

11 tial basis for developing novel rapid-acting antidepressant therapies.

12 After discontinuation of antidepressant therapy, 92 patients with clinically defi

13 ectivity with the DN as a brain mechanism of antidepressant therapy action.

14 cronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression

15 ptors and adenylyl cyclase may underlie both antidepressant therapy and depressive illnesses.

16 Current antidepressant therapies are effective in only some pati

17 y modest and differences in efficacy between antidepressant therapies are small.

18 S) therapy, a fast-acting and very effective antidepressant therapy, are poorly understood.

19 with a recent depression diagnosis who began antidepressant therapy but had not used antidepressants

20 sociations for manic/hypomanic states during antidepressant therapy, current mixed mood symptoms, and

21 of 114 untreated depressed patients started antidepressant therapy during hospitalization (nine with

22 A majority of the patients discontinued antidepressant therapy during the first 30 days (42.4%).

23 uring hospitalization, only 11% received any antidepressant therapy during the median 11-month follow

24 Optimized antidepressant therapy followed by a pain self-managemen

25 ment recommend 4 to 9 months of continuation antidepressant therapy following remission of acute symp

26 Research into antidepressant therapies for TRD has evolved from explor

27 on treatment guidelines recommend continuing antidepressant therapy for at least 4 to 9 months, many

28 those remaining on their initial regimens of antidepressant therapy for at least 6 months were more l

29 ed to fully assess the benefits and risks of antidepressant therapy for bipolar disorder.

30 Only 27.6% of the patients continued antidepressant therapy for more than 90 days.

31 receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51

32 until safety and efficacy are determined for antidepressant therapy in patients who recently have had

33 287,543 adults aged 18 years and older with antidepressant therapy initiated, we observed outcome ra

34 Mood disorders and antidepressant therapy involve alterations of monoaminer

35 Early discontinuation of antidepressant therapy is widespread in the community tr

36 nse, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequate

37 ly contribute to depressive disorders, while antidepressant therapies may enhance GABAergic synaptic

38 However, antidepressant therapy may be beneficial for patients wh

39 nt large randomized trials suggest tricyclic antidepressant therapy may be effective in functional dy

40 -controlled trial to evaluate the effects of antidepressant therapy on symptoms, gastric emptying (GE

41 tment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a match

42 ent for erectile dysfunction associated with antidepressant therapy or subsyndromal depression.

43 was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depre

44 amethasone, growth factors, nitric oxide and antidepressant therapies regulate the expression of p11.

45 n who are euthymic in the context of ongoing antidepressant therapy should be aware of the associatio

46 ervention consisted of 12 weeks of optimized antidepressant therapy (step 1) followed by 6 sessions o

47 Donepezil and antidepressant therapy temporarily improved global cogni

48 bition ratio represents a novel strategy for antidepressant therapies that reproduces behavioral and

49 o patients with depression who are beginning antidepressant therapy to improve depressive symptoms mo

50 Intensity of antidepressant therapy was predicted by severity of depr

51 om their primary care physician thought that antidepressant therapy was warranted and who completed a

52 The two well-established chemical antidepressant therapies were also ineffective, indicati

53 ll as well as before and after initiation of antidepressant therapy were compared for patients who re

54 Characteristics of patients receiving antidepressant therapy were examined to identify factors

55 mood stabilizer with or without concomitant antidepressant therapy were randomly assigned to receive

56 Antidepressant therapy with 15 to 45 mg/d of mirtazapine